Keeping checkpoint kinases in line: new selective inhibitors in clinical trials - PubMed (original) (raw)
Review
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
Susan Ashwell et al. Expert Opin Investig Drugs. 2008 Sep.
Abstract
Background: Checkpoint kinase 1 (Chk1), a serine/threonine kinase, functions as a regulatory kinase in cell cycle progression and is a critical effector of the DNA-damage response. Inhibitors of Chk1 are known to sensitise tumours to a variety of DNA-damaging agents and increase efficacy in preclinical models.
Objective: The most advanced agents are now in Phase I clinical trials; the preclinical profiles of these drugs are compared and contrasted, together with a discussion of some of the opportunities and challenges facing this potentially revolutionary approach to cancer therapy.
Methods: A review of the publications and presentations on XL-844, AZD7762 and PF-477736.
Results/conclusions: Chk kinases are part of the DNA damage recognition and response pathways and as such represent attractive targets. Agents that target checkpoint kinases have demonstrated impressive evidence preclinically that this approach will provide tumour-specific potentiating agents and may have broad therapeutic utility.
Similar articles
- Checkpoint kinase inhibitors: a review of the patent literature.
Janetka JW, Ashwell S. Janetka JW, et al. Expert Opin Ther Pat. 2009 Feb;19(2):165-97. doi: 10.1517/13543770802653622. Expert Opin Ther Pat. 2009. PMID: 19441917 Review. - Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
Li Q, Zhu GD. Li Q, et al. Curr Top Med Chem. 2002 Sep;2(9):939-71. doi: 10.2174/1568026023393318. Curr Top Med Chem. 2002. PMID: 12171565 Review. - Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H. Chen Z, et al. Int J Cancer. 2006 Dec 15;119(12):2784-94. doi: 10.1002/ijc.22198. Int J Cancer. 2006. PMID: 17019715 - CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
McNeely S, Beckmann R, Bence Lin AK. McNeely S, et al. Pharmacol Ther. 2014 Apr;142(1):1-10. doi: 10.1016/j.pharmthera.2013.10.005. Epub 2013 Oct 15. Pharmacol Ther. 2014. PMID: 24140082 Review. - Inhibitors of checkpoint kinases: from discovery to the clinic.
Janetka JW, Ashwell S, Zabludoff S, Lyne P. Janetka JW, et al. Curr Opin Drug Discov Devel. 2007 Jul;10(4):473-86. Curr Opin Drug Discov Devel. 2007. PMID: 17659489 Review.
Cited by
- Mitochondria dysfunction in circulating tumor cells.
Agnoletto C, Volinia S. Agnoletto C, et al. Front Oncol. 2022 Aug 4;12:947479. doi: 10.3389/fonc.2022.947479. eCollection 2022. Front Oncol. 2022. PMID: 35992829 Free PMC article. Review. - Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors.
Malvacio I, Cuzzolin A, Sturlese M, Vera DMA, Moyano EL, Moro S. Malvacio I, et al. J Enzyme Inhib Med Chem. 2017 Dec;33(1):171-183. doi: 10.1080/14756366.2017.1404592. J Enzyme Inhib Med Chem. 2017. PMID: 29210298 Free PMC article. - Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.
Prince EW, Balakrishnan I, Shah M, Mulcahy Levy JM, Griesinger AM, Alimova I, Harris PS, Birks DK, Donson AM, Davidson N, Remke M, Taylor MD, Handler MH, Foreman NK, Venkataraman S, Vibhakar R. Prince EW, et al. Oncotarget. 2016 Aug 16;7(33):53881-53894. doi: 10.18632/oncotarget.10692. Oncotarget. 2016. PMID: 27449089 Free PMC article. - Inhibition of autophagosome-lysosome fusion by ginsenoside Ro via the ESR2-NCF1-ROS pathway sensitizes esophageal cancer cells to 5-fluorouracil-induced cell death via the CHEK1-mediated DNA damage checkpoint.
Zheng K, Li Y, Wang S, Wang X, Liao C, Hu X, Fan L, Kang Q, Zeng Y, Wu X, Wu H, Zhang J, Wang Y, He Z. Zheng K, et al. Autophagy. 2016 Sep;12(9):1593-613. doi: 10.1080/15548627.2016.1192751. Epub 2016 Jun 16. Autophagy. 2016. PMID: 27310928 Free PMC article. - Family-wide Structural Analysis of Human Numb-Associated Protein Kinases.
Sorrell FJ, Szklarz M, Abdul Azeez KR, Elkins JM, Knapp S. Sorrell FJ, et al. Structure. 2016 Mar 1;24(3):401-11. doi: 10.1016/j.str.2015.12.015. Epub 2016 Feb 4. Structure. 2016. PMID: 26853940 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous